FORM 2 THE PATENTS ACT 1970 [39 OF 1970] & THE PATENTS RULES, 2003 COMPLETE SPECIFICATION [See Section 10; rule 13] "PROCESS FOR THE PREPARATION OF NOVEL INDOLIN-2-ONE COMPOUND" SANOFI-SYNTHELABO, of 174, Avenue de France, F-75013 Paris, France, The following specification particularly describes the invention and the manner in which it is to be performed: The present invention relates to compound in the form of a pure enantiomer or of a mixture of enantiomers of indolin-2-one. A subject matter of the present invention is novel indolin-2-one derivatives, a process for their preparation and the pharmaceutical compositions comprising them. These novel derivatives are powerful and selective ligands of the oxytocin receptors and can thus be used as an active principle in pharmaceutical compositions, in particular in the obstetric or gynaecological field. Oxytocin (OT) is a hormone excreted by the neurohypophysis with a cyclic nonapeptide structure similar to that of arginine vasopressin (AVP). The oxytocin receptors are essentially found on the smooth muscle of the uterus and on the myoepithelial cells of the mammary glands. Thus, oxytocin plays an important role in parturition since it is involved in the contraction of the uterine muscle and in lactation. Furthermore, oxytocin receptors are also located in other peripheral tissues and in the central nervous system; oxytocin can thus have effects in the cardiovascular, renal, endocrinal or behavioural fields. Indolin-2-one derivatives have been disclosed in some patent applications as ligands of the vasopressin receptors and possibly of the oxytocin receptors; mention may be made of Patent Applications WO 93/15051; EP 636 608, EP 636 609, WO 95/18105, WO. 97/15556. and WO 98/25901. To date, no indolin-2-one derivative has been disclosed as a powerful and selective ligand of oxytocin receptors. It has now been found that certain indolin-2-one derivatives are powerful and selective ligands of oxytocin receptors. in which: - Ro represents a group chosen from; in which: Thus, according to one of its aspects, the present invention relates to novel indolin-2-one derivatives in the form of a pure enantiomer or a ' mixture of enantiomers of formula: Z1 represents a chlorine, bromine, iodine or fluorine atom or a (C1-C4) alkyl, (C1-C4) alkoxy or trifluoromethyl group; Z2 represents a hydrogen, chlorine, bromine, iodine or fluorine atom or a (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkoxy, (C3-C5) cycloalkoxy or (C1-C4) polyfluoroalkyl group; R5 represents TiW in which Ti represents -(CH2)m,it being possible for m to be equal to 0 or 1, and W" 'v represents a hydrogen atom or a hydroxycarbonyl (or carboxyl), (C1-C4)alkoxycarbonyl, 1,3-dioxolan-2-yl or 1,3-dioxan-2-yl group, or else W represents an -NR6R7 group inv which Rs and R7 represent, independently of one another, a hydrogen atom, a (C1-C4)alkyl group, a (C1-C4)alkylsulphonyl group or a phenylsulphonyl .group in which the phenyl group can be mono-, di- or trisubstituted by Z5; or else R6 and R7 form, with the nitrogen atom to which they are bonded, a morpholinyl group optionally substituted.by a (C1-C4) alkyl group or an oxo; or e.lse Re and R7 form, with the nitrogen atom to which they are bonded, a " piperazinyl group optionally substituted in the -4-position by a Z3 substituent; or else R6 and R7 form, with the nitrogen atom to which they are bonded, a pyrrolidinyl or piperidyl group, the said pyrrolidinyl and piperidyl groups optionally being substituted by Z4; or else W represents an -NR8COR9 group in which Rs represents a hydrogen atom or a (C1-C4)alkyl group and R9 represents a hydrogen atom or a (C1-C4)alkyl, benzyl, pyridyl or phenyl group, it being possible for the said phenyl group to be mono-, di- or trisubstituted.by Z5; or else R9 represents an -NR10R11 group in which R10 and R12 represent, independently of one another, a hydrogen atom or a (C1-C4) alkyl [lacuna] or else R10 and R13 form, with the nitrogen atom to which they are bonded, a. pyrrolidinyl, piperidyl or- morpholinyl group optionally substituted by a (C1-C4) alkyl group; or else Rg represents a pyrrolidin-2-yl or -3-yl or 15 piperid-2-yl, -3—yl or -4-yl group, the said pyrrolidinyl and piperidyl groups optionally being substituted by Z7; or else R9 represents a -T2-R12 or -T2-COR12 group in which T2 represents -(CH2)n-/ it being possible for n to be equal to 1, 2, 3 and 4, and R12 represents a (C1-C4) alkoxy or -NR10R11 group, R10 and R11 being as defined above; or else W represents a -CONR13R14_ group in which R13 represents a hydrogen atom or a (C1-C4) alkyl, (C3-C7) cycloalkyl, 25 monofluoro (C1-C4) alkyl or polyfluoro (C1-C4) alkyl group and R14 represents a hydrogen atom, a (C1-C4)alkyl group, a phenyl group optionally substituted by Z5, a -T4-R15 group in which T4 . represents -(CH2)q, with q equal to 1, 2, 3 or 4, and R15 represents a hydroxyl group, a (C1-C4) alkoxy group, a (C1-C4) alkoxycarbonyl group, a (C1-C4)alkoxycarbonylamino group, a phenyl group optionally mono- or disubstituted by Z5, a pyrid-2-yl, -3-yl or -4-yl, or an -NR16R17 group in which R16 and R17 represent, independently of one another, a hydrogen atom or a (C1-C4)alkyl [lacuna] or else R16 and R17 form, with the nitrogen atom to which they are bonded, a morpholinyl group optionally mono- or disubstituted by a (C1-C4)alkyl group or else R16 and R17 form, with the nitrogen atom to which they are bonded, a piperazinyl' group optionally substituted in the 4-position by a Z3 substituent or else R16 and R17 form, with the nitrogen atom to which they are bonded, a pyrrolidinyl or piperidyl group, the said pyrrolidinyl and piperidyl groups optionally being substituted by Z5, it being understood that, when q = 1, R15 is other than hydroxyl, (C1-C4) al'koxy, (C1-C4) alkoxycarbonylamino or -R16-R17 or else R13 and R14 form, with the nitrogen atom to which they are bonded, a morpholinyl group optionally mono- or. disubstituted by a (C1-C4)alkyl group or a piperazinyl group optionally substituted in the 4-position by a Z3 substituent; or else R13 and R14 form, with the nitrogen atom to which they are bonded, an azetidinyl, pyrrolidinyl, piperidyl or hexahydroazepinyl group, the said pyrrolidinyl, piperidyl and hexahydroazepinyl groups optionally being mono- or disubstituted by Z8; or else W represents an OR18 group in which R18 represents a hydrogen atom or a (C1-C4) alkyl, (C1-C4) alkoxy (C1-C4) alkyl or -T3-R19- group in which T3 represents -(CH2)P-, it being possible for p to be If) equal to 2 or 3, and R19 is chosen from the hydroxyl, triphenylmethoxy or -NR20R21 groups in which R20 represents a hydrogen atom or a (C1-C4) alkyl group and R21 represents a hydrogen atom or a (C1-C4) alkyl, I te'trahydrofuranylmethyl or tetrahydropyranylmethyl 15 group, or else R20 and R21 form, with the nitrogen atom to which they are bonded, a morpholinyl group optionally mono- or disubstituted by a (C1-C4) alkyl group or a piperazinyl group optionally substituted in the 4-position by a Z3 substituent, or else R20 and R21 form, with the nitrogen atom to which they are bonded, a pyrrolidinyl or piperidyl group, the said pyrrolidinyl and piperidyl groups optionally being substituted by Z5; - Z3 represents a (C1-C4) alkyl, pyridyl, phenyl, (C1-C4) alkylca-rbonyl or (C1-C4) alkoxycarbonyl group; Z4 represents an oxo, a fluorine atom, a hydroxyl, a (C1-C4) alkyl, a benzyl, an amino, a (C1-C4) alkylamino, a di (C1-C4) alkylamino, a (C1-C4) alkoxy, a (C1-C4) alkoxycarbonyl or a (C1-C4) alkoxycarbonylamino; Z5 represents a chlorine, bromine, iodine or fluorine atom, a hydroxyl group, a (C1-C4)alkyl group or a (C1-C4) alkoxy group; Z7 represents a-fluorine atom, a hydroxyl group, a hydroxy (C1-C4) alkyl group, a (C1-C4) alkyl [lacuna], a (C1-C4) alkoxy [lacuna] or a (C1-C4) alkylcarbonyl [lacuna]; Z8 represents a fluorine atom or a hydroxyl, (C1-C4) alkyl, (C3-C6) cycloalkyl, benzyl, amino, (C1-C4) alkylamino, di (C1-C4) alkylamino, (C1-C4) alkoxycarbonyl, (C1-C4) alkoxycarbonylamino, (C3-C6) cycloalkoxy, hydroxycarbonyl, hydroxy (C1-C4) alkyl, (C1-C4) alkoxy (C1-C4) alkyl, (C1-C4) alkoxy or -CONR23R24 group in which R23. and R24 represent, independently of one another, a hydrogen atom, a (C1-C4)alkyl, a monofluoro (C1-C4) alkyl or a polyfluoro (C1-C4) alkyl, or else R23 and R24 form, with the nitrogen atom to which they are bonded, a pyrrolidinyl or piperidyl group, the said pyrrolidinyl or piperidyl groups optionally being substituted by Z3 or a difluoromethylidene; Z6 represents a chlorine atom or a (C1-C4)alkyl or (C1-C4) alkoxy group; R1 represents a (C1-C4)alkyl group optionally comprising a double or a triple bond, a (C1-C4)alkoxycarbonyl group, a phenyloxycarbonyl group or a T2'-R22 group in which T1 is as defined above and R22 represents a hydroxyl or (C1-C4) alkoxy group; R2 and R4 represent, independently of one another, a hydrogen, chlorine or fluorine atom or a (C1-C4) alkyl or (C3.-C4) alkoxy group; R3 represents a chlorine or fluorine atom or a (C1-C4) alkyl, (C1-C4) alkoxy, hydroxyl, (C1-C4) carbamoyl, (C1-C4) alkylcarbonylamino, nitro, cyano, trifluoromethyl, amino, (C3-C6) cycloalkylamino, (C1-C4) alkylamino, di (C1-C4) alkylamino,1 tri (C1-C4) alkylammonium A", A" being an anion, pyrrolidin-1-yl, piperid-1-yl, piperazin-1-yl, morpholin-4-yl or hexahydroazepin-1-yl group; X and Y represent, independently of one another, a hydrogen, chlorine, bromine, iodine or fluorine atom or a (C1-C4) alkoxy or trifluoromethoxy group; and to their pharmaceutically acceptable salts, their solvates and their hydrates. The term "alkyl" is understood to mean a saturated, linear or branched, monovalent hydrocarbonaceous radical. The term M (C1-C4) alkyl" is understood to mean an alkyl radical comprising from 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. The term "alkylene" is understood to mean a saturated, linear or branched,.bivalent hydrocarbonaceous radical. The 'term "alkoxy" is understood to mean an O-alkyl radical. The term "anion A~" is understood to mean, for, example, a C1", Br, I" or CH3S04". The term "di (C1-C4) alkylamino" is understood to mean an amino radical substituted by two alkyl radicals which can be identical or different. In the same way, for tri (C1-C4)"ammoniums, the alkyl radicals can be identical or different- The salts of the compounds according to the invention are prepared according .to techniques which are well known to a person skilled in the art. The salts of the compounds of formula (I) according to the present invention comprise those with inorganic or organic acids, which make possible suitable separation or"crystallization of the compounds of formula (I), and pharmaceutically acceptable salts. Mention may be made, as appropriate acid, of: picric acid, oxalic acid or an optically active acid, for' example a tartaric acid, a dibenzoyltartaric acid, a mandelic acid or a camphorsulphonic acid, and those which form physiologically acceptable salts, such as the hydrochloride, the hydrobromide, the sulphate, the hydrogensulphate, the dihydrogenphosphate, the maleate, the fumarate, the 2-naphthalenesulphonate or the para-toluenesulphonate, the hydrochloride being preferred. When a compound according to the invention exhibits one or more asymmetric carbons, the optical isomers of this compound form an integral part of the invention. When a compound according to the invention exhibits stereoisomerism, for example of axial-equatorial or Z-E type, the invention comprises all the stereoisomers of this compound. The present invention comprises the compounds of formula (I) in the form of pure isomers but also in the form of a mixture of isomers in any proportion. The compounds (I) are isolated in the form of. pure isomers by conventional separating techniques: use may be made, for example, of fractional recrystallizations of a salt of the racemate with an optionally active acid or base, the principle of which is well known, or conventional chromatography -techniques on a chiral or nonchiral phase. The'compounds of formula (I) above also comprise, those in which one or more hydrogen, carbon o halogen, in particular iodine, chlorine or fluorine, atoms have been replaced by their radioactive isotope, for example tritium or carbon-14. Such labelled compounds are of use in research, metabolic or pharmacokinetic studies or in biochemical assays as receptor ligand. The functional groups possibly present in the molecule of the compounds of formula (I) and in the reaction intermediates can be protected, either in permanent form or in temporary form, by protective groups which ensure unequivocal synthesis of the expected compounds. The protection and deprotection reactions are carried out according to techniques well known to persons skilled in the art. The term "temporary protective, group for amines or alcohols" is understood to mean protective groups such as those described in Protective Groups in Organic Synthesis, Greene T.W. and Wuts P.G.M., published by Wiley Intersciences, 1999, and in Protecting Groups, Kocienski P.J., 1994, Georg Thieme Verlag. Mention may be made, for example, of temporary protective groups for amines: benzyls, carbamates (such as tert-butyloxycarbonyl, which can be cleaved in acidic medium, or benzyloxycarbonyl, which can be cleaved by hydrogenolysis); for carboxylic acids: alkyl esters (such as methyl, ethyl or tert-butyl esters, which can hydrolyse in basic or acidic medium) and benzyl esters, which can be hydrogenolysed; for alcohols or for phenols, such as tetrahydropyranyl, methyloxymethyl, methylethoxymethyl, tert-butyl and benzyl ethers; or for carbonyl derivatives, such as linear or cyclic acetals, like, for example, 1,3-dioxane-2-yl or 1,3-dioxolan-2-yl; and reference may be made to the well known general methods described in the abovementioned Protective Groups. A person skilled in the art will be in a position to choose the appropriate protective groups. The compounds of formula (I) can comprise precursor-groups of other functional groups which are subsequently generated in one or more other stages. One family of compounds according to the invention is composed of indolin-2-one derivatives in the form of a pure enantiomer or of a mixture of enantiomers of formula: in which: R0 represents *> Zi, Z2, R1, R2, R3, R4, R5, Y and X are as defm (I), and their pharmaceutically acceptable salts, their solvates and their hydrates. According to another of its aspects, the invention relates to the compounds of formula: in which R1 represents a methyl or hydroxyl group and Ro, R2, R3, R4, X and Y are as defined for (I); in the form of a pure enantiomer or of a mixture of enantiomers, and their pharmaceutically acceptable salts, their solvates and their hydrates. A subfamily of the compounds according to the invention is composed of the compounds of formula: in which R1. represents a methyl or hydroxyl group and Ro, R3/ R4 and X are as defined for (I); in the form of a pure enantiomer or of a mixture of enantiomers, and their pharmaceutically acceptable salts, their solvates and their hydrates. Another subfamily of the compounds according .to the invention is composed of .the compounds of formula: in which R1 represents a methyl or hydroxyl.group and R0 and R3 are as defined for (I); in the form of a pure enantiomer or of a mixture of enantiomers, and their pharmaceutically acceptable salts, their solvates and their hydrates. Another subfamily of the compounds according to the invention is composed of the compounds of formula: in which R2 represents a methyl or hydroxyl group and Ro is as defined for (I); in the form of a pure enantiomer or of a mixture of enantiomers, and their pharmaceutically acceptable salts, their solvates and their hydrates. Among these compounds of formula (I), (la)/ (lb), (Ic) and (Id), those in which Ro represents the group: in which R5 is as defined for'(I), constitute another aspect of the invention. Among the latter compounds, those in which Rx represents a methyl group constitute another aspect of the invention. According to another of its aspects, the invention relates to the compounds chosen from: 5-Chloro-3-(2-chlorophenyl)-1-(2,4-dimethoxybenzyl)-3-methylindolin-2-one (Example 1); 5-Chloro-3-(2-chlorophenyl)-1-[4-(isopropylamino)-2-methoxybenzyl]-3-methylindolin-2-one (Example 56); 2V-{4-Chloro-3- [5-chloro-l- (2, 4-dimethoxybenzyl) -3-methyl-2-oxoindolin-3-yl]phenyl}acetamide (Example 70).; W-{4-Chloro-3~[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]phenyl}-3-methylbutanamide (Example 73)_ N-{4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]phenylJbenzamide (Example 74) ; N-{4-Chloro-3-[5-chloro-l-(2, 4-dimethoxybenzyl)-| 3-methyl-2-oxoindolin-3-yl]phenyl}nicotinamide (Example 7 6) ; 2V-{4-Chloro-3- [5-chloro-l- (2, 4-dimethoxybenzyl) -3-methyl-2-oxoindolin-3-yl]phenyl}-2-methoxyacetamide (Example 77) ; Methyl 3-{4-chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]anilino}-3-oxopropanoate (Example 78); N-{4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)- 3-methyl-2-oxoindolin-3-yl] phenyl} -3-methoxypropanamide (Example 81) ; N-{4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)- 3-methyl-2-oxoindolin-3-yl]phenyl}-W-methylacetamide (Example 87) ; 20 W-{4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)- 3-methyl-2-oxoindolin-3-yl]phenyl}-N-methylmethane-sulphonamide (Example 97) ; 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]-N,N-diethylbenzamide (Example 102); 5 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]-N,N-dime thy Ibenz amide (Example 109); 5-Chloro-3-[2-chloro-5-(1-piperidylcarbonyl)phenyl]- 1-(2,4-dimethoxybenzyl)-3-methylindolin-2-one (Example 112) ; 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]-iV-ethylbenzamide (Example 114); 5-Chloro-3-(2-chloro-5-{[2-(methoxymethyl)-1-pyrrolidinyl]carbonyl}phenyl)-1-(2,4-dimethoxy¬benzyl) -3-methylindolin-2-one (Example 119); 5-Chloro-3-{2-chloro-5-[(2-methyl-l-piperidyl)-carbonyl]phenyl}-l-(2,4-dimethoxybenzyl)-3-methyl- 10 indolin-2-one (Example 122); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl] -N-ethyl-N-methylbenzamide (Example 124) ; Methyl l-{4-chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)- 3-methyl-2-oxoindolin-3-yl]benzoyl}-2-piperidine-carboxylate (Example 131) ; 5-Chloro-3-{2-chloro-5-[(4-hydroxy-l-piperidyl)-carbonyl]phenyl}-!-(2,4-dimethoxybenzyl)-3-methyl-indolin-2-one (Example 134); 5-Chloro-3-{2-chloro-5-[(2-methoxyethoxy)methyl]- phenyl}-l-(2,4-dimethoxybenzyl)-3-methylindolin-2-one (Example 142) 5-Chloro-3-[2-chloro-5-(4-morpholinylmethyl)phenyl]-1-(2,4-dimethoxybenzyl)-3-methylindolin-2-one 25 (Example 148) ; 5-Chloro-3-(2-chloro-5-{[2-(4-morpholinyl)ethoxy]-methyl}phenyl)-1-(2,4-dimethoxybenzyl)-3-methylindolin- 2-one (Example 152}; 1- [4-Chloro-3-.[5-chloro-l- (2,4-dimethoxybenzyl) 3-methyl-2-oxoindolin-3-yl]benzoyl]-3-hydroxypiperidine (Example 194) ; 1-[4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)- 3-methyl-2-oxoindolin-3-yl]benzoyl]-(R)-3-hydroxy¬piperidine (Example 195); l-[4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)- 3-methyl-2-oxoindolin-3-yl]benzoyl]-4-methoxypiperidine (Example 166) ; 1-[4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]benzoyl]-4-ethoxypiperidine (Example 167); 1- [4-Chloro-3-.[5-chloro-l- (2,4-dimethoxybenzyl)-3-methyl^2-oxoindolin-3-yl]benzoyl]-(R,S)-2, 6-dimethyl-piperidine (Example 18 9)'; 1-[4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]benzoyl]-(R)-2-ethoxy-carbonylpiperidine (Example 17 5); 1-[4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl] benzoyl] - (R) -2-N,N-dimethyl aminocarbonylpiperidine (Example 169); 1-[4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]benzoyl]-(R)-2-(N-methyl-N-2,2,2-trifluoroethylaminocarbonyl)piperidine (Example 17 0); 1-[4-iChloro-3-[5-chloro-l-(2, 4-dimethoxybenzyl) - . 3-methyl-2-oxoindolin-3-yl]benzoyl]-(R)-2-pyrrolidino-carbonylpiperidine (Example 168); 1-[4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]benzoyl]-(S)-2-methyl-piperidine (Example 174) ; 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]-N-ethyl-N-(2-phenylethyl)benzamide (Example 185); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]-N-ethyl-N-(4-pyridylmethyl)benzamide hydrochloride (Example 188); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl] -iV-ethyl-N- (3-pyridylmethyl) benzamide (Example 201) ; 4-Chloro-3- [5-chloro-l- (2, 4-dimethoxybenzyl) -3-methyl-2-oxoindolin-3-yl]-N-ethyl-N-(2-pyridylmethyl)benzamide (Example 200) ; 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl] -N-ethyl-N- (2-methoxyethyl) benzamide (Example 184) ; 4-Chloro-3-[5-chloro-l—(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl] -N-ethyl-N- (2-dimethylaminoethyl) -benzamide hydrochloride (Example 177); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]-N-ethyl-N- (2-morpholinoethyl)-benzamide (Example 178); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl- 2-oxoindolinr3-yl] -iV-ethyl-W- (2-pyrrolidinoethyl) - benzamide hydrochloride (Example 182); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl- 2-oxoindolin-3-yl] -N-ethyl-IV- (2-piperidinoethyl) - benzamide hydrochloride (Example 183); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl- 2-oxoindolin-3-yl]-N-ethyl-N-(2-hydroxyethyl)benzamide (Example 198); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl- 2-oxoindolin-3-yl]-W-ethyl-N-[2-(pyrid-4-yl)ethyl]-benzamide hydrochloride (Example 179); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl- 2-oxoindolin-3-yl]-N-ethyl-N-(2,2,2-trifluoroethyl)- benzamide (Example 180); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl- 2-oxoindolin-3-yl]-N-methyl-N-(2,2,2-trifluoroethyl)- benzamide (Example 171); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl- 2-oxoindolin-3-yl]~N-ethyl-N-isopropylbenzamide (Example 187); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]-N-(2-dimethylaminoethyl)-N- (2,2,2-trifluoroethyl)benzamide hydrochloride (Example 202); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindolin-3-yl]-N-cyclohexylbenzamide (Example 192); 4-Chloro-3-[5-chloro-l-(2,4-dimethoxybenzyl)-3-methyl-. 2-oxoindolin-3-yl] -W-ethyl-JV- [3- (pyrid-4-yl)propyl] -benzamide (Example 204); . in the form of a pure enantiomer or of a mixture of enantiomers, and to their pharmaceutically acceptable salts, their solvates and their hydrates. The compound of formula (I) can be prepared according to the following Scheme 1: SCHEME 1 (IV) 03- 1 In this scheme,. Ro, ■ R1, R2, R3,- R4,- Xand Y are as defined for (I) and, for (Ip) , R'o,- R1, R'2, R3 R'4, X' and Y' respectively represent either Ro, Ri, R2, R3, R4,- X and Y as defined for (I) or a precursor group for Ro, R1, R2/ R3, R4, X and Y, it being understood that R'1 is other than hydrogen. Another subject-matter of the present invention is a preparation process for the compounds of formula (I), characterized in that: 0 a) a compound of formula: ^ R, (H) Y N0 1.) in which X, Y, Ro and Ri are as defined for (I) , -is reacted in the presence of a base with a halide of formula: 20 in which Hal represents a halogen -atom and R2, R3 and R4 are as defined for (I); b) or else, when Ri represents an- ele'ctrophilic % group, the compound of formula: c) in which R0, R2, R3, R4, X and Y are as defined for (I), is converted by the action of a derivative Ri-Z, in-which Z represents a leaving group, in the presence of a base; or else, when Rx = OH, .an isatin derivative of formula: - . ■ / in which R2, R3, R4, X and Y are as defined for (I) , is reacted with an organometallic. derivative R0-M or R0MgHal, R0 being as defined for (I), M being a metal atom and Hal being a bromine or iodine atom; or else the compound of formula: in which R'0, R'1, R'2, R'3, R4, X' and Y' respectively represent either Ro, R1, R2, R3, R4, X and Y as defined for (I) or a precursor group for R0, Ri, R2, R3, R4, X and Y, is subjected to a subsequent treatment to convert any one of the. R'o, R,1, R'2 R'3 R'4, X' and Y' groups to respectively R0, R1, R2/ R3, R4, X or Y as defined for (I), according to reactions well known to a person skilled in the art. • The reaction described in a) is preferably . Carried out'with a compound (1) in which Hal. = CI or Br using, as base, a metal hydride, such as sodium hydride, or an alkali metal alkoxide, such as potassium tert-butoxide, in an anhydrous solvent, such as dimethylformamide or tetrahydrofuran. 6 In the reaction described in b), the term "leaving group" is understood to mean, for example, a halogen atom, such as chlorine, bromine or iodine, or alternatively a sulphonic ester group, such as para-toluenesulphon'ate. The compound (III) is 0 preferably reacted with a halide R1-Hal, Ri being as defined for (I) and Hal being a halogen atom, preferably an iodine atom, in the presence of a base; the reaction will be carried out, for example, in the presence of a base, such as an alkali.metal alkoxide, 5 for instance potassium tert-butoxide, in an ethereal solvent, such as tetrahydrofuran, or alternatively in the presence of a carbonate, such as sodium, potassium- or caesium carbonate, in a solvent such as dimethylformamide or acetonitrile. 2 Advantageously, in the reaction described in c), the compound of formula (IV) is reacted with a magnesium derivative R0Mg-Hal, R0 being as defined for (I) or (Ip) and Hal being a bromine or preferably iodine atom, or alternatively the compound (IV) is 25 ' reacted with a derivative R0M in which M is preferably a lithium atom. This derivative RoLi is obtained either by direct lithiation, for example by the action of butyllithium or lithium diisopropylamide according to Heterocycles, 1993, 35(1), 151-169, or by a halogen-lithium exchange reaction according to Organolithium Methods, Pergamon Press, New York, 1988 or J. Am. Chem. Soc., 1956, 2217. These reactions are preferably carried out in an anhydrous solvent, such as diethyl ether or tetrahydrofuran. The conversion of the compound (Ip), the precursor of the compound (I), described in d) is carried out according to conventional techniques. Furthermore, the compounds '(I) can be obtained from another compound (I) by conversion of one of the R0, R1, R2, R3, R4, X or Y substituents, in particular Ro, R1 or R3 substituents. For example: the compounds (I) in which R3 = -NH2 can be obtained by reduction of the corresponding compounds (I) in which R3 = -N02, for example by the action of hydrochloric acid in the presence of tin in an alcohol, such as ethanol; the compounds (I) in which R3 represents a (C1-C4) alkylamino or di (C1-C4) alkylamino group can be obtained from the corresponding compounds (I) in which R3 =. -NH2 by a reductive amination reaction. Reference may be made to J. Org. Chem., 1996, 61, 3849-3862 and the reaction can be carried out by the-action of a (C1-C4alky! aldehyde in the presence of sodium triacetoxyborohydride or alternatively reference may be made to J. Am. Chem. Soc, 1974, 96(25), 7812 and the reaction can be carried out by the action of a (C1-C4) alkyl acid in the presence of sodium borohydride. Use may also be made of conventional N-alkylation reactions, for example by reacting the amino group with a (C1-C4) alkyl halide in the presence of dimethylformamide and potassium carbonate; the compounds (I) in which R3 represents a (C1-C4)alkoxy can be obtained from the corresponding compounds (Ip) in which R'3 = OH by a conventional O-alkylation reaction, for example by the action of a (C1-C4) alkyl halide" in the presence of dimethylformamide and of caesium or potassium carbonate; the compounds (I) in which R3 represents a (C1-C4)alkylcarbonylamino group can be obtained from the corresponding compounds (I) in which R3 = -NH2 by a conventional acylation, such as the action of a (C1-C4)alkyl acid chloride in the presence of a base, such as trie-thylamine, in a solvent, such as dichloromethane; the compounds (I) in which R3 represents a cyclic amine or a morpholin-4-yl can be obtained from the corresponding compounds (I) in which R3- = -NH2 according to the method described in Tetrahedron, 1989, 45(3), 629-636. - the compounds of formula (I) in which- R0 represents a group: can be obtained from the corresponding compounds of formula (I) by conversion of the R5 group according to conventional reactions, for example alkylation, acylation, oxidation, reduction or amination reactions, well known to a person skilled in the art. The.compounds (III) are prepared by dehalogenation of the compounds of formula: 5 in which R0, /R2, R3, . R4, X and Y are as defined for. (I) and Hal represents a chlorine, bromine or iodine atom, for example by the action of a hindered lithium. dialkylamide, such as lithium diisopropylamide (LDA) ,. by analogy with the method described by N. Newcom et al. in J. Am. Chem. Soc., 1990, 5186-5193. The compound (I') is, for example, obtained by conversion of the corresponding compound (I) in which R1 = OH by the action of a halogenated derivative, for example of acid halide type. Mention may be made, as chlorinated derivative, of SOCl2 The compound (IV) is generally obtained by reaction of the compound (1) with the isatin derivative of formula: in which X and Y are as defined for (I), under the same conditions .as those described above for the preparation of the compound (I) from the compound (II). The isatin derivatives (2) are commercially available compounds or are prepared according to the methods described in Tetrahedron Letters, 1998, 39, -7679-7682; Tetrahedron Letters, 1994, 35, 7303-7306; J. Org. Chem., 1977, 42, 1344-1348 and Advances in Heterocyclic Chemistry, A.R. Katritzky and A.J. Boulton, Academic Press, New York, 1975, 18, 2-58. The compounds (II) can be synthesized according to various methods disclosed, in particular in Patent Applications EP 526 348' and WO 95/18105. Some routes for the production of the compounds (II) are illustrated in Scheme 2: SCHEME 2 The term "nucleophilic R1" is understood to mean a (C1.-C4) alkoxy group. The compounds (II)' in which R1 represents an electrophilic group, for example a- (C1-C4)alkyl group, can be prepared from the compounds of formula: in which R0, X and Y are as defined for (I), by reaction with a derivative R1-Z in which Z represents a leaving group,.under the same conditions as those described above for the transformation of the compound (III) to the compound (I). The compound (V) is generally synthesized: • either by dehydroxylation of the corresponding compound (II) in which R1 - OH by the action of tin chloride in acidic medium, according to the method described in Tetrahedron, 1996, 52(20), 7003-7012, or l(p by the action of triethylsilane, according to Bioorganic and Medicinal Letters, 1997, 7(10), 1255-12 60; • or by a cyclization reaction in a strong acid medium, such as, for example, sulphuric acid, of the compound . of. formula: in which Ro, X and Y are as defined for (I), this 10 compound (VII) itself being obtained by a condensation reaction between an a-hydroxyacetic acid derivative of formula: R0 being as defined for (I), with an aminobenzene of formula: in which X and Y are as defined for (I). The compounds (3) are commercially available or are conventionally synthesized. The compounds of formula (VIII) are commercially available or are synthesized according"to methods well known to a person skilled in the art. Reference may in particular be made to J. Med. Chem., 1987, 30(8), 1447. Other reactions can also lead to the compounds (V). Mention may be made of: . - the Brunner reaction described in Tetrahedron, 1986,. 42(15) , 4267-4272: the • cyclization reaction in the presence, of formic acid described in J. Ch'em. Soc. PerKin Trans., 1986, 1. - the following cyclization reactions according to Tetrahedron,. 1996, 52(20), 7003-7012. , " The compounds (II) in which Ri represents a (C1_C4)alkoxy group are obtained from the compounds of formula: X in which R0, X and Y are as defined for (I) and Hal represents a halogen atom, for example a chlorine atom, by the action of the corresponding alcohol RiH. . The compound (VI) is prepared from .the . yf 1 corresponding compound (II) in which R1 = OH by reaction with thionyl chloride in the presence of pyridine in dichloromethane. The compounds (II) in which R1 = OH are 5 generally prepared from the corresponding isatin of formula: in which X and Y are as defined for (I) , according to the method described above for the preparation of the 0 compounds (I) in which R1 = OH from the compounds (IV) When R1 does not represent a hydroxyl group, the compounds (II) can also be prepared according to Scheme 3 below: In this Scheme 3, RQ, RI, X and Y are as defined for (I), R1 does not represent a hydroxyl group and M represents, for example,,a lithium atom or MgHal, Hal being a halogen atom. The transformation of the compound (X) to the compound (IX) to give the compound (II) is carried out in particular according to the method described in J. Chem. Soc, 1957, 1928. 7 The benzyl halides (1) are known or are prepared according to known methods. Mention may be made, for example, of J.V. Rajanbabu, J, Org. Chem., 1986, 51, 1704-1712 and the publications cited in |5 EP 636 609. Generally, the halomethylbenzene derivatives (1) can be prepared by the action of N-halosuccinimides on the corresponding methylbenzene derivatives and according to EP 229 566. The reaction is carried out in 10 a solvent, such as carbon tetrachloride, in the presence of dibenzoyl peroxide. A halomethylbenzene derivative can also be prepared from a corresponding hydroxymethylbenzene derivative by reaction with phosphorus tribromide in diethyl ether or by reaction 5 with thionyl chloride. At any stage in the process, an intermediate compound of (Up), (IIIp) or (IVp) type, in which at least one of the substituents is replaced by one of its precursor groups, can be formed intermediately. These 20 compounds (Up), (IIIp) and (IVp) will be converted by conventional reactions into (II), (III) and (IV)- respectively. A person skilled in the art will be in a position to adapt the abovementioned reactions to the compounds (Up) , (IIIp) and (IVp) . 25 . The compounds according to the invention have formed the subject of biochemical and pharmacological studies. The affinity of the compounds according to the invention for oxytocin receptors was determined in an in vitro binding test using the method described by J. Elands et al. in Eur. Pharmacol., 1987, 141, 192-207. This method consists in studying in vitro the 3 displacement of a radioiodinated oxytocin analogue at the oxytocin receptors in a membrane preparation of human uterine oxytocin receptors. The IC50 values (concentration which inhibits 50% of the binding of the radioiodinated oxytocin analogue to its receptors) are 101 low and vary from 10"10 to 10"6 M in the latter test. The affinity of the compounds according to the invention for human vasopressin Via receptors (method described by M. Thibonnier et al. in J. Biol. Chem., 1994, 269, 3304-3310), Vlb receptors (method 15 described by T. Sugimoto et al. in J. Biol. Chem., 1994, 269,. 27088-27092) and V2 receptors (method described by M. Birnbaumer et al. in Nature (Lond.), 1992, 357, 333-335) has also been studied. The compounds studied have little or no affinity for the 20 Vla, Vib and V2 receptors. By way of indication, the compound of Example 1 exhibits an IC50 of les's than 50 nM, the IC50 values with respect to the Via, Vib and V2 receptors being greater than 1 uM. The agonist or antagonist nature of the 25 compounds is determined in vitro in a test for the measurement of intracellular calcium with respect to cells expressing human oxytocin receptors according to the general technique described in Am, J. Physiol., 268 (Heart Circ. Physiol., 37), 1995, H404-H410. When the compounds according to the invention behave as antagonists, their IC50 is advantageously between 0.5 uM and 0.5 nM. By way of example, the dextrorotatory enantiomer of Example 1 is an antagonist with an IC50 of 3.2 ± 1.9 nM. The compounds according to the invention, powerful and selective ligands of oxytocin receptors, are particularly advantageous in the prevention and/or treatment of oxytocin-dependent disorders. The compounds according to the present invention can either mimic or inhibit the effects of oxytocin. They will be particularly advantageous in cicatrization, in .analgesia and anxiolysis (prevention of pain and anxiety), depression, schizophrenia, autism, obsessive compulsive syndrome, in maternal behaviour (facilitation of mother-child recognition and acceptance) and social behaviour, memory, regulation of food and drink intake, dependence on drugs, weaning and sexual motivation. They can be advantageously used in disorders of the urogenital sphere,.in particular in the obstetric and gynaecological fields, in particular as uterine relaxant or tocolytic agent or for controlling contractions of the uterus before pregnancy has arrived at term, for controlling prenatal labour or for controlling preparatory labour for the purpose.of a caesarean delivery, for solving problems of sterility or fertility, controlling births (in particular veterinary use), controlling oestrus, the halting of breast feeding, weaning' or embryo transfer and 5 implantation; treating endometriosis, dysmenorrhoea and hypertrophy and erectile dysfunctions, hypertension, hyponatraemia, cardiac insufficiency, atherosclerosis or angiogenesis, and regulating the storage of fat by' 0 the adipocyte. Further more' given the role of oxytocin in controlling luteinizing hormone (J.J. Evans, J. Endocrin., 1996,151 ' 169-174), the compounds of the invention can be' used to induce contraception. Furthermore the compounds according to the invention can be used for their antitumour effects in oxytocin-secreting tumours, in particular- breast and prostate cancers. The use of the compounds according to 0 invention for the prevention and/or the treatment of the abovementioned conditions and for the preparation of medicaments intended to treat these conditions forms an integral part of the invention. Another subject-matter of the present invention is thus pharmaceutical compositions comprising a compound according to the invention or a pharmaceutically.acceP table salt, solvate or hydrate of the latter and suitable excipients. The said excipients are chosen according to the pharmaceutical form and the method of administration desired: oral, sublingual, subcutaneous, intramuscular, intravenous, topical, 5 intratracheal, intranasal, transdermal, rectal or intraocular. The pharmaceutical compositions are prepared according to techniques known to a person skilled in the art. In order to obtain the desired prophylactic-10 or therapeutic effect, each unit dose can comprise from 0.5 to 1 000 mg, preferably from 1 to 500 mg, of active ingredients in combination with a pharmaceutical vehicle. This unit dose can be administered 1 to 5 times daily, so as to administer a daily dosage of 0.5 15 to 5 000 mg, preferably from 1 to. 2 500 mg. The compounds according to the invention can also be used for the preparation of compositions for veterinary use intended to regulate births. The compounds according to the invention can 20 also be used for the preparation of cosmetic compositions. These formulations can be provided in the form of a cream for topical use and will be intended to 1 control lipolysis. 1 The compositions of the present invention can 25 1 comprise, in addition to the products of formula (I) 1 above or their pharmaceutically salts, solvates and hydrates, [lacuna] and for example active principles which may be of use in the treatment of the disorders or conditions indicated above. Thus, another subject-matter of the present invention is pharmaceutical compositions comprising several active principles in combination, one of which is a compound according to the invention. In particular, the present invention relates to pharmaceutical compositions comprising a compound according to the invention, an antagonist of oxytocin receptors, with- a Vla antagonist compound. This type of composition will be of particular use in the treatment of dysmenorrhoea or endometriosis or the control of premature labour and for controlling preparatory labour for the purpose of a caesarean delivery. Another subject-matter of the invention is products comprising an antagonist of oxytocin receptors as defined above and an antagonist of vasopressin Via receptors for simultaneous or separate use or use spread out over time in the treatment of dysmenorrhoea or endometriosis or the control of premature labour and for controlling preparatory labour for the purpose of a caesarean delivery. The following PREPARATIONS and EXAMPLES illustrate the invention without, however, limiting it. The nuclear magnetic resonance spectra were recorded in deuterated chloroform, unless otherwise mentioned, at 200 MHz and" the chemical shifts are expressed in ppm. The abbreviations used below are as follows: s = singlet; m = multiplet; -d = doublet, t = triplet; q = quintet. All the compounds according to the invention have formed the object of organic elemental analysis carried out by combustion at 1 000°C in the presence of oxygen using a balance of Supermicro S4 Sartorius type and an elemental analyser of EA 1108 type. The percentage analyses of the elements carbon, hydrogen, If) nitrogen and sulphur obtained are in agreement with the theoretical results expected. PREPARATIONS PREPARATION 1 5 N- (4-Chlbrophenyl)-2-oxopropionamide, compound XI.1. 26.3 g of 4-chlorophenylamine in 150 ml of J - dichloromethane and 35 ml of triethylamine are added, at -60°C, to 22 g of 2-oxopropionyl chloride (prepared according to Synthesis, 1975, 163-164 from 2-oxopropionic acid and 1,1-dichlorodimethyl ether) in 350 ml of dichloromethane. The reaction mixture is stirred at -60°C for 2 hours and then 200 ml of a 0.15N aqueous hydrochloric acid solution and 500 ml of dichloromethane are added at -30°C. The organic phase 5 is extracted, washed with a 0.25N aqueous hydrochloric acid solution and dried over sodium sulphate. The solvents are evaporated under reduced pressure and the residue obtained is crystallized from dichloromethane;■ M.p. = 151°C. PREPARATION 2 2-(2-Chloro-4-fluorophenyl)-N- (4-chlorophenyl)-2- hydroxypropionamide, compound IX.1. 0.18 g of magnesium and 2.57 g of 2-chloro-4-fluoro-1-iodobenzene are stirred at reflux in 30 ml of diethyl ether. The mixture thus obtained is added at -60°C to 0.99 g of compound XI.1 in 9 ml of tetrahydrofuran. The reaction mixture is stirred at 20°C for 2 hours and then a saturated aqueous NH4C1 solution is added. Extraction is carried out with ethyl acetate, the organic phase is dried over Na2S04 and the solvents are evaporated under reduced pressure. The residue obtained is purified by chromatography on a column of silica gel, elution being carried out with a 1/1 (v/v) cyclohexane/dichloromethane mixture and then a 99/1 (v/v) dichloromethane/methanol mixture. The solid thus isolated is crystallized from diisopropyl ether; M.p. 167°C. The following compounds are.prepared in the same way: N- (4-ChIorophenyl)-2-(2,5-dimethoxyphenyl)-2-hydroxypropionamxde, compound IX.2; M.p. 145°C. N- (4-Chlorophenyl)-2-(2-chloro-4-methylphenyl)-2-hydroxypropionamide, compound IX.3; M.p. 1160c. N- (4-ChIorophenyl)-2-(2-chloro-5-methyIphenyl)-2-hydroxypropionamide, compound IX.4; M.p. 14 7 ° C. N- (4-Chlorophenyl)-2-(2-chloro-5-fluorophenyl)-2-hydroxypropionamide, compound IX.5; M.p. 171°C. PREPARATION 3 (2-Chlorophenyl)-N- (4-chlorophenyl)hydroxyacetamide, compound VI1.1. A mixture of 60 g of (2-chlorophenyl)hydroxy-10 acetic acid and 41 g of 4-chlorophenylamine in 300 ml of 1,2-dichlor.obenzene is heated to 200°C. The setup comprises a Dean and Stark apparatus and thus the water formed is removed during the reaction. Approximately 150 ml of solvent are distilled off and the expected compound is crystallized at 20°C. The solid obtained is rinsed with diisopropyl ether; M.p. = 120°C. In the same way, (2-chlorophenyl)-N- (4-methoxyphenyl)hydroxyacetamide, compound VII.2, is prepared from 4-methoxyphenylamine; M.p. = 130°C. In the same way, (2-chloro-4-fluorophenyl)-N-(4-chlorophenyl)hydroxyacetamide, compound VII.3, is prepared from (2-chloro-4-fluorophenyl)hydroxyacetic acid (synthesized according to J. Med. Chem., 1987, 30 (8), 1447, from 2-chloro-4-fluOrobenzaldehyde and bromoform); M.p. = 136°C. PREPARATION 4 5-Chloro-3-(2-chlorophenyl)indolin-2-one, compound V.l 10 A solution of 263 ml of 95% sulphuric acid and 100 ml of 20% oleum is prepared at 10°C. This solution is stirred with 74-g of compound VII.1 for 2 hours at 40°C. The reaction mixture is subsequently' cooled and then poured onto ice-cold water. The precipitate obtained is filtered off and then washed with 1 000 ml of water. The solid is dissolved in dichloromethane and the solution thus obtained is washed successively with a saturated aqueous sodium hydrogencarbonate solution and with water and then dried over Na2S04. The solvents are evaporated under reduced pressure and then the solid obtained is washed with diethyl ether; M.p. = 201°C. Compound V.2 below is prepared in the same way:■ . . 0 5-Chloro-3-(2-chloro-4-fluorophenyl)indolin-2-one, compound V.2. ^ PREPARATION 5 5-Methoxy-3-(2-chlorophenyl)indolin-2-one, compound V.3. 20.1 g of 2-(2-chlorophenyl)-N-(4-methoxy-5 .phenyl)-2-hydroxyacetamide, compound VII.2, are added to a mixture of polyphosphoric acid, obtained from 65 ml of 85% phosphoric acid and 130 g of phosphorus pentoxide, at a temperature of 50°C and then the reaction mixture is maintained at this temperature for 10 16 hours. After cooling, treatment is carried out with Ian aqueous sodium hydrogencarbonate solution until a pH [of 5 is obtained. Extraction is carried out with ethyl acetate. The organic phase is washed with water and then dried over anhydrous sodium sulphate. The solvent 15 j is partially evaporated under reduced pressure and the expected product is filtered off; M.p. = 179°C. PREPARATION 6 5-Chloro-3-(2-chlorophenyl)-3-methylindolin-2-one, compound II.1. 18.2 g of potassium tert-butoxide are added at -40°C to a solution of 15 g of compound V.1 in 240 ml of tetrahydrofuran. The reaction mixture is stirred at 0°C for 5 minutes- and then a solution of 3.7 ml of methyl iodide in 80 ml of tetrahydrofuran is added at -60°C. Once the temperature of the reaction mixture has returned to 0°C, 100 ml of a saturated aqueous ammonium chloride solution are added and extraction'is carried out with ethyl acetate. The 5 organic phase is washed with water and then dried over anhydrous sodium sulphate. The solvents are evaporated under reduced pressure. The solid obtained is purified by chromotagraphy on a column of silica gel, elution being carried out with a 1/9 (v/v) ethyl 10| acetate/cyclohexane mixture. The solid obtained is crystallized from n-pentane; M.p. = 185°C- Compounds II.2 to II.6 below are prepared in the same way. A TABLE 1 Compound Ro R1 M.p,; °C A -CH2— C=CH II.2 219 —CH2—CH=CH2 II.3 218 ; —CH2CH3 II.4 198 CH2CH2CH3" II.5 ■ 218 -CH3 II.6 189 5-Methoxy-3-(2-chlorophenyl)-3-methylindolin-2-one, compound II.7, is prepared according to the same procedure from 5-methoxy-3-(2-chlorophenyl)indolin-2-one; M.p. = 176°C. PREPARATION 7 5-Chloro-3~(2~chloro-4-fluorophenyl)-3-methylindolin-2- one, compound II.6 & Compound II. 6, described above, can also be prepared as follows: 0.3 g of compound IX.1 and a solution, prepared beforehand, of 5.3 g of phosphorus pentoxide in 3 ml of an 85% aqueous phosphoric acid solution are heated to 150°C for 5 hours. The reaction mixture is poured onto ice, a saturated aqueous potassium carbonate solution is added and extraction is carried out with ethyl acetate. The organic phase thus obtained is dried over anhydrous sodium sulphate. The solvents are evaporated under reduced pressure. The solid obtained is crystallized from n-pentane; M.p. = 189°C. The compound 5-chloro-3-(2,5-dimethoxyphenyl)-3-methylindolin-2-one, compound II.8; OCH3 is prepared in the same way. M.p. = 163°C. PREPARATION 8 5-Chloro-3-[2-chloro-5-(4-methyl-l-piperazinyl)phenyl]- 3-methylindol-2-one, compound II.9. ^ The mixture composed of 0.5 g of compound II.6, 2.5 ml of dimethyl sulphoxide, 3.6 ml of N-methylpiperazine, 1 g of sodium carbonate and 0.1 g of cuprous iodide is heated at 120°C for 24 hours. After returning to room temperature, the salts are filtered off through talc and the precipitate is rinsed with dimethyl sulphoxide and then with 60 ml of ethyl acetate. The filtrate is washed with 40 ml of water and the organic phase is dried over anhydrous sodium sulphate. The solvents are evaporated under reduced pressure and the residue is purified by chromatography on a column of silica gel, elution being carried out with dichloromethane. The expected product is isolated after taking up the solid residue in diisopropyl ether and then filtering; M.p. = 155°C. PREPARATION 9 5-Chloro-3-(2-chloro-4-fluorophenyl)-3-hydroxyindolin- 2-one, compound 11.10. 0..44 g of a 60% dispersion of sodium hydride in oil is added at -40°C to a cooled suspension of 2 g of 5-chloroindolin-2,3-dione in 60 ml of tetrahydrofuran and the reaction mixture is stirred at 0°C for -15 minutes. 0.45 g of magnesium and 4.23 g of 2-chloro-4-fiuoro-l-iodobenzene in 18 ml of diethyl 5 ether are stirred at reflux for 3 hours. The solution thus obtained is slowly added at -60°C to the reaction mixture. The reaction mixture is stirred for 30 minutes at 20°C and a saturated aqueous ammonium chloride 'solution is added. Extraction is carried out with ethyl acetate, the organic phase is dried over anhydrous sodium sulphate and the solvents are evaporated under reduced pressure. The residue obtained is purified by chromatography on a column of silica gel, elution being carried out with dichloromethane and then with a 95/5 (v/v) dichloromethahe/methanol mixture. The solid obtained is crystallized from n-pentane; M.p..= 239°C. In the same way, 5-chloro-3-(2,5-dimethoxyphenyl)-3-hydroxyindolin-2-one, compound is prepared from l-bromo-2, 5-dimethoxybenzene. M.p. ="221°C. PREPARATION 10 3,5-Dichloro-3-(2,5-dimethoxyphenyl)indolin-2-one , compound VI.1. OCH3 0.8 ml of thionyl chloride is added, at a temperature of less than 20°Cf to 3 g of compound 11.11 in the presence of 1.2 ml of pyridine in 50 ml of dichioromethane and then the reaction mixture is stirred for one hour. The reaction mixture is washed with water and dried over anhydrous sodium sulphate. The solvents are evaporated under reduced pressure and then the residue, is chromatographed on a column of silica gel, elution being carried out with dichioromethane. M.p. = 157°C. The following compounds are prepared in the same way: 3,5-Dichloro-3-(2-chlorophenyl)indolin-2-one, compound VI. 2. M.p. = 190°C - 3,5-Dichloro-3-(2-chloro-4-fluorophenyl)indolin-2-one, compound VI.3. PREPARATION 11 5-Chloro-3-(2,5-dimethoxyphenyl)-3-methoxyindolin-2- one, compound 11.11. 0.4 g of compound VI.1 in the presence of 25 ml of methanol in 50 ml of tetrahydrofuran is maintained at reflux for 3 hours. The solvents are evaporated under reduced pressure. M.p. - 180°C. The following compounds are prepared in the same way: 5-Chloro-3-(2-chlorophenyl)-3-methoxyindolin-2-one, compound II.12. 5-Chloro-3-(2-ehloro-4-fluorophenyl)-3-methoxyindolin-2-one, compound 11.13. PREPARATION 12 5-Chloro-l-(2,4-dimethaxybenzyl)indolin-2,3-dione, compound IV.1. (IV.1.) : R2 = H; R3 = 4-OCH3; R4 = 2-OCH3; X = 5-C1; Y = H a) 0.25 ml of phosphorus tribromide is added at -50°C to a suspension of 1.45 g of 2,4-dimethoxyphenyl-methanol in 25 ml of diethyl ether. The solution thus obtained is allowed to return to a temperature of.0°C. b) 2 g of potassium tert-butoxide are added at -60°C to a suspension of 1.3 g of 5-chloroindolin-2,3-dione in 50 ml of tetrahydrofuran. The reaction mixture is stirred at 0°C for 5 minutes and then the solution prepared in a) is added at -60°C. The reaction.mixture is stirred at room temperature for 16 hours and then the solvents are evaporated under reduced pressure. The residue obtained is purified by chromatography on a column of silica gel, elution being carried out with a cyclohexane/dichloromethane mixture varying from 8/2"to 2/8 (v/v). The solid obtained is crystallized from toluene; M.p. = 175°C. The following compounds are prepared in the same way: 5-Cnloro-l-(4-chloro-2-methoxybenzyl)indolin-2,3-dione, Compound IV.2. M.p. = 136°C 5,7-Dichloro-l-(2,4-dimethoxybenzyl)indolin-2,3-dione, Compound IV.3. M.p. = 171°C 5-Fluoro-l-(2,4-dimethoxybenzyl)indolin-2,3-dione, Compound IV.4. M.p. = 163°C 1-(2,4-Dimethoxybenzyl)indolin-2,3-dione, Compound IV. 5. M.p. = 142°C. EXAMPLE 1 5-Chloro-3-(2-chlorophenyl)-1-(2,4-dimethoxybenzyl)-3- methylindolin-2-one. R3 = 4-OCH3; R4 = 2-OCH3; X = -5-CI; Y = H a) 0.48 ml of phosphorus tribromide is added at -50CC to a suspension of 2.6 g of 2,4- dimethoxyphenylmethanol in 45 ml of diethyl ether. The solution thus obtained is allowed to return to a temperature of 0°C. b) 1.2 g of potassium tert-butoxide are added at -40°C to 3 g of compound II.1 in solution in 90 ml of tetrahydrofuran and then the reaction mixture is stirred until the temperature has returned to 0°C. The reaction mixture is subsequently cooled to -60°C and the solution prepared in a) is added. The reaction mixture is stirred at 20°C for 2 hours, 50 ml of water are added and extraction is carried out with ethyl acetate. The organic phases are dried over sodium sulphate and the solvents are evaporated under reduced pressure. The- solid obtained is crystallized from diisopropyl ether; M.p. = 179°C. This compound, in the racemic form, is then separated by chromatography on a Chiralpak® AD column from Daicel, elution being carried out with a 98/2 (v/v) 2-methylpentane/ethanol mixture. The dextrorotatory enantiomer: M.p. = 92 °C; r i23-5 = +39c (c = 1,CH3OH) ,and its antipode are thus isolated. . . EXAMPLE 2 5-Methoxy-3-(2-chlorophenyl)-1-(2,4-dimethoxybenzyl)-3- methylindolin-2-one. R3 = 4-OCH3; R4 = 2-OCH3; X = 5-OCH3; Y - H The compound of Example 2 is prepared according to the same procedure from 5-methoxy-3-(2-chlorophenyl)indolin-2-one, compound II. 7; M.p. = 133°C. EXAMPLE 3 5-Chloro-3-(2-chlorophenyl)-1-[4-(1,1-dimethylethoxy) 10| 2-methoxybenzyl]-3-methylindolin-2-one. a) Preparation of [4-(1,1-dimethylethoxy)-2-methoxy]phenylmethanol 15 • Preparation of methyl [4-(1,1-dimethylethoxy)-2- methoxyjbenzoate according to J. Org. Chem., 1986, 51, 111-113. 0.25 ml of trifluoromethanesulphonic acid is added at-70°C to 6.2 g of methyl 4-hydroxy-2- 20 methoxybenzoate (according to J. Med. Chem., 1985, 28, 717-727, from commercial methyl 2,4-di'hydroxybenzoate) in 60 ml of dichloromethane and then 25 ml.of 2-methylpropene, condensed beforehand at -20°C and degassed by natural rewarming, are added by means of a dip pipe. After stirring for 24 hours at a temperature of between -30 and -70°C, .0.5 ml of triethylamine is added to the reaction mixture. The solvents are evaporated under reduced pressure and the residue is taken up in ethyl acetate and washed with a dilute sodium bicarbonate solution. The separated organic phase is dried over anhydrous sodium sulphate and the solvents are evaporated under reduced pressure. The expected product is isolated, purification being carried out by chromatography on a column of silica gel,, elution being carried out with cyclohexane. XH NMR: 7.75 (d, 1H) , 6.62-653 (m, 2H)', 3.85 (s, 3H), 3.84 (s, 3H), 1.40 (s, 9H) According to J. Chem. Soc. Perkin Trans., 1991/ -3291-3294. 15.90. ml of a 2M solution of LiBH4 in tetrahydrofuran are added to 2.5 g of the preceding compound obtained in a) in 25 ml of toluene. The reaction mixture is heated at 100°C for 45 minutes. At approximately 20°C, the reaction mixture is poured onto a water/ice mixture and the aqueous phase is extracted with ethyl acetate. After separating by settling, the aqueous phase is extracted with ethyl acetate. The organic phases are combined and dried over anhydrous sodium sulphate and then the solvents are evaporated under reduced pressure. XH NMR: 7.10 (d, 1H), 6.59-6.50 (m, 2H), 4.61 (d, 2H) , 3.81 (s, 3H) , 2.20 (t, 1H), 1.34 (s, 9H). b) The compound of Example 3 is prepared according to the same procedure as for Example 1; M.p. = 131°C. EXAMPLE 4 5-Chloro-3-(2-chIorophenyl)-1-[4-(1-methylethoxy)-2- methoxybenzyl]-3-methylindolin-2-one. a) Preparation of [4-(1-methylethoxy)-2-methoxy]phenylmethanol. • Preparation of methyl [4-(1-methylethoxy)-2- methoxyjbenzoate according to Synthesis, 1988, 712. 2.86 g of caesium carbonate and then 1.28 ml of 2-iodopropane are added at 0°C to 0,8 g of methyl 4-hydroxy-2-methoxybenzoate in 20 ml of dimethylformamide. The reaction mixture is stirred at 20°C for 2 hours, 50 ml of water are then added and extraction, is carried out with ethyl "acetate. The organic phase is washed with water and then .dried over anhydrous sodium sulphate. The solvents are evaporated under reduced pressure. 1H NMR: 7.81 (d, 1H), 6.47-6.42 (m, 2H) , 4.69-4.51 (m, 1H) , 3.85 (s, 3H) , 3.83 (s, 3H), .1.33 (d, 6H) . [4-(1-Methylethoxy)-2-methoxyphenyl]methanol is prepared according to the method described above in Example 3 for the transformation of methyl [4-(1,1-dimethylethoxy)-2-methoxy]benzoate into [4-(1,1-dimethylethoxy)-2-methoxy]phenylmethanol. b) The compound of Example 4 is prepared according to the procedure described for Example 1; M.p. = 158°C. Examples 5 to 17 below are prepared according to the procedure described for Example 1. EXAMPLE 5 5-Chloro-3-(2-chlorophenyl)-1-(2-methoxy-4- nitrobenzyl)-3-methylindolin-2-one. CI. R3 = 4 -N02 ; R4 = 2-OCH3 ; X = 5-CI ; Y = H M.p. - 179°C. »> 62 EXAMPLE 6 5-Chloro-l-(2,4-dimethoxybenzyl)-3-(2,5- dimethoxyphenyl)-3-methylindolin-2-one. 63 TABLE 2 EXAMPLE R1 M.p.; °C; salt, hydrate 7 —CH2—C=CH 135 8 —CH2—CH=CH2 117 9 —CH2CH3 102 10 —CH2CH2CH3 119 EXAMPLE Ro R4 M.p.; °C 11 2-0CH3 155 12 3-OCH3 150 13 •2-OCH3 121 14 2-OCH3 wax. & TABLE EXAMPLE R0 M.p.;°C 15 112 16 . 168 17 113 EXAMPLE 18 5-Chloro-3- (2-chloro-4-fluorophenyl) -1- (2,4- dimethoxybenzyl)-3-hydroxyindolin-2-one. R3 = 4-OCH3; R4 = 2-OCH3; X = 5-CI; Y = H This compound can be prepared from compound 11.10 according to the same procedure as for Example 1 .J' or else according to the method below: 0.87 ml of 2-chloro-4-fluoro-l-iodobenzene and 0.09 g of magnesium in 15 ml of diethyl ether are stirred at reflux for 1 hour. 0.75 g of compound IV. 1, in partial solution in 15 ml of tetrahydrof.uran, is added at -40°C. The reaction mixture is stirred for ,2 hours at 20°C and then a saturated aqueous ammonium- chloride solution is added. Extraction is carried out with ethyl acetate, the organic phase is dried over anhydrous sodium sulphate and then the solvents are 15 evaporated under reduced pressure. The' residue obtained is purified by chromatography on a column of silica gel, elution being carried out with a 1/1 (v/v) cyclohexane/dichloromethane mixture. The solid obtained is crystallized from cyclohexane; M.p. ■= 177°C. 2p This compound, in the racemic form, is separated by chromatography on a Chiralpak® AD column from Daicel, elution being carried out with a 9/1 (v/v) 2-methylpentane/ethanol mixture. The dextrorotatory enantiomer: • isolated. EXAMPLE 19 5-Chloro-3-(2-chloro-5-methoxymethoxymethylphenyl)-1- (2,4-dimethoxybenzyl)-3-hydroxyindolin-2-one. R3 = 4-OCH3; R4 = 2-OCH3; X = 5-C1; Y = H a) Preparation of 2-chloro-l-iodo-5- hydroxymethylbenzene according to J. Org. Chem., 1991, 56, 5964-5965, from the corresponding commercial benzoic acid. 5.02 g of s,odium borohydride are added portionwise and then 14.6 g of iodine, in solution in 50 ml of tetrahydrofuran, are added very slowly to 25 g of 4-chloro-3-iodobenzoic acid in solution in 200 ml of tetrahydrofuran at 0°C. The reaction mixture is stirred for 2 hours at room temperature and then at 35°C for 30 minutes. Hydrolysis is carried out at 10°C with a 0.5N hydrochloric acid solution and extraction is carried out with ethyl acetate. The organic phase is separated by settling and then treated with an aqueous sodium bisulphite solution and then with water. The organic phase is dried over anhydrous sodium sulphate and the solvents axe evaporated under reduced pressure. The expected compound is obtained by distillation; B.p. = 109°C under 3 Pa. b) Preparation of 2-chloro-l-iodo-5- methoxymethyleneoxymethylbenzene according to Synthesis, 1985, 74. 1.5 ml of para-toluenesulphonic acid monohydrate and 1.4 g of lithium bromide are added to 24.45 g of the preceding compound in 100 ml of dimethoxymethane. The reaction mixture is stirred at 35°C for 4 hours and then for 2 hours at reflux. Hydrolysis is carried out at room temperature with a dilute aqueous sodium bicarbonate solution and extraction is carried out with diethyl ether. The organic phase is washed with water and dried over anhydrous sodium sulphate and the solvents are evaporated under reduced pressure. The expected product is obtained by distillation; B.p. = 108°C under 1.9 Pa. c) The compound of Example 19 is prepared according to the procedure described for Example 18; 69 EXAMPLE 20 Methyl 4-chloro-3-[5-chloro-l- (2,4-dimethoxybenzyl)-3- hydroxy-2-oxoindolin-3-yl]benzoate R3 = 4-OCH3; R4 = 2-OCH3; X = 5-C1; Y = H 45.2 ml of a 1. 6M solution of .n-butyllithium in hexane, diluted in 2G0 ml of tetrahydrofuran .and cooled to -90°C, are slowly added to 10.72 g of methyl 4-chloro-3-iodobenzoate (prepared by esterification of the corresponding commercial acid; M.p; = 56°C) in 200 ml of tetrahydrofuran"cooled to -100°C. The reaction mixture is stirred at -95°C for 20 minutes and then the solution, cooled to -70°C, of 10 g of compound IV. 1 in 600 ml of.. tetrahydrofuran is added. After returning to room temperature, hydrolysis is carried out with 200 ml of a saturated ammonium chloride solution, the solvents are partially evaporated under reduced pressure, extraction is carried out with ethyl acetate, the organic phase is dried over anhydrous sodium sulphate and then the solvents are evaporated under reduced pressure. The residue obtained is washed with diethyl ether, filtered off and then dried at 50°C under reduced pressure; M.p. = 236°C. . EXAMPLE 21 3- (5-Amino-2-chlorophenyl) -5-chloro-l- (2,4- dimethoxybenzyl)-3-hydroxyindolin-2-one R3 - 4-OCH3; R4 = 2-OCH3; X = 5-C1; Y = H a) Preparation of 4-chloro-3-bromo-N,N- (tetramethyl-ethylene)disilylaniline A mixture composed of 3.3 g of 3-bromo-4-chloroaniline, 3.72 g of bis(dimethylaminodimethyl- 1( silyl) ethylene, obtained according to Tetrahedron Letters, 1984, 25 (12), 1253-1254, and 0.03 g of zinc iodide is heated at 14 0°C for 5 hours under an argon stream. The expected.product is distilled; B.p. = 105°C under 37 Pa. b) The compound of Example 21 is prepared according to the same procedure described for Example 20, purification being carried out by chromatography on a column of silica gel, elution being carried out with a 99/1 (v/v) dichloromethane/methanol mixture; 2p M.p. = 133°C. The compounds"- of Examples 22 to 31 below are-prepared in the same way as for Example 18: EXAMPLE Ro M.p; °C; salt, hydrate 22 156 23 185 24 190 0.7, H20 25 207 .. 26 198 27 186 TABLE 5 (continuation) EXAMPLE Ro M.p.; °C; salt, hydrate 28 196 29 199 30 161 31 148 EXAMPLE 32 5-Chloro-l-(2,4-dimethoxybenzyl)-3-[5-(l,3-dioxolan-2- yl)-2-methoxyphenyl]-3-hydroxyindolin-2-one. a) Preparation of 2-(3-bromo-4-methoxyphenyl)-1,3- , dioxolane according to J. Med. Chem.; 1990, 33(3), 972. A mixture composed of 5 g of 3-bromo-para- anisaldehyde, 5 ml of ethylene glycol, 0.088 g of para-toluenesulphonic acid and 125 ml of toluerie is heated at reflux for 1 hour 30 minutes in a reactor equipped with a Dean and Stark apparatus. The reaction mixture 5 is poured at room temperature onto-50 ml of water, extraction is carried out with diethyl ether and the organic phase is dried over anhydrous sodium sulphate. 'The solvents are evaporated under reduced pressure. The oil obtained is purified by chromatography on a column . of silica gel, elution being carried out with an 8/2 (v/v) cyclohexane/ethyl acetate mixture. The expected product is obtained after,distillation under reduced pressure; B.p. = 128°C under 5 Pa. b) The compound of Example 32 is prepared from 5 the preceding compound according to the procedure described for Example 18; M.p. = 140°C. EXAMPLE 33 5-Chloro-l-(2,4-dimethoxybenzyl)-3-{5-[(dimethylamino)- ; 10 methyl]-2-methoxyphenyl}-3-hydroxyindolin-2-one H3CO a) 3-[5-Chloro-l-(2,4-dimethoxybenzyl)-3-hydroxy-2-oxoindolin-3-yl]-4-methoxybenzaldehyde, obtained by deprotection of the compound of Example 32 in acidic 2)5 medium according to J. Chem. Soc. Chem. Commun., 1987, 1351. The mixture composed of 0.55 g of the compound of Example 32, 5 ml of acetone, 2.5 ml of water and 0.22 ml of IN hydrochloric acid is brought to 5 30°C for 2 hours with stirring. The reaction mixture is neutralized at room temperature with an aqueous sodium bicarbonate solution and extraction is carried out with ethyl acetate. The organic phase is dried over, anhydrous sodium sulphate, the solvents are evaporated 1 ) under reduced pressure and the desired compound is obtained by filtration of the evaporation residue taken up in diethyl ether; M.p. = 189°C. b) Reductive amination according to J. Org. Chem., 1996, 61(11), 3849-3862. - 0.015 g of dimethylamine, in solution in 1 ml of 1,2-dichloroethane, and then 0.072 g of sodium triacetoxyborohydride are added to 0.113 g of the preceding compound obtained" in a) in suspension in 3 ml of 1,2-dichloroethane. After stirring for 15 hours at 2C room temperature, hydrolysis is carried out with 10 ml of water and extraction is carried out with ethyl " acetate. The organic phase is dried over sodium sulphate, the solvents- are evaporated under reduced I pressure and the residue obtained is purified by 25 \ chromatography on a column of silica gel, elution being \carried out with a 95/5 (v/v) dichloromethane/methanol mixture. The expected product is. obtained after crystallization from isopropyl ether; M.p. = 162°C (0.4 H20) EXAMPLE 34 5-Chloro-3-(3-chloropyridin-4-yl)-1-(2,4-dimethoxy- benzyl)-3-hydroxyindolin-2-one. A solution of 0.414 ml of 3-chloropyridine in 5 ml of tetrahydrofuran is added dropwise to a solution, diluted in 7 ml of tetrahydrofuran and cooled to ~75°C, of 2.88 ml of 1.5 M lithium diisopropylamide in cyclohexane. After the addition, the reaction mixture is stirred at -75°C for 20 minutes and then 1.2 g of compound IV.1 in 15 ml of tetrahydrofuran are added. The temperature of the reaction mixture is allowed to slowly rise to 0°C and then hydrolysis is carried out with 30 ml of an aqueous ammonium chloride solution. Extraction is carried out with ethyl acetate and the organic phase is dried over sodium sulphate. The solvents are evaporated under reduced pressure and the residue obtained is purified by chromatography on a column of silica gel, elution being carried out with a 75/25 (v/v) cyclohexane/ethyl acetate mixture-. The solid obtained is subsequently crystallized from ethyl 10 77 acetate; M.p. = 215°C. The compounds of Examples 35 and 3 6 below are prepared in'the same way: TABLE 6 EXAMPLE Ro M.p.; °C; salt, hydrate 35 210 36 215 PREPARATION 13 5-Chloro-3-(2-chlorophenyl)-1- (2,4- dimethoxybenzyl)indolin-2-one, compound III.1. 19 a) 3,5-Dichloro-3-(2-chlorophenyl)-1- (2,4-dimethoxybenzyl)indolin-2-one, compound I'.l, 0.98 ml of thionyl chloride is added at -20°C to a solution of 2 g of the compound of Example 30 and 1.4 ml of pyridine in 24 ml of dichloromethane. The reaction mixture is stirred for 1 hour 30 min at room temperature and is cooled to 0°C a'nd then 5 0 ml of water and 50 ml of dichloromethane are added. Separation is carried out by settling, the organic phase is washed with an aqueous NaHC03 solution and dried over anhydrous sodium sulphate, and the solvent is evaporated under reduced pressure. The residue obtained is dried under reduced pressure for 2 hours and compound I'.l is isolated in the form of a resin which is used directly in the following stage, b) Compound III.l 6.53 ml of a 1.5M solution of lithium diisopropylamide in cyclohexane, rediluted with 15 ml of tetrahydrofuran, are added at -68°C to the solution of compound I'.l obtained above in 24 ml of tetrahydrofuran. The reaction mixture is stirred for 45 minutes at -68°C and then 5 ml of methanol are slowly added. At approximately 0°C, water is added and extraction is carried out with ethyl acetate. The organic phase is washed with an aqueous sodium chloride solution and dried over sodium sulphate and the solvent is evaporated under reduced pressure. The residue obtained is purified by chromatography on a column of silica gel, elution being carried out with an 85/15 (v/v) cyclohexane/ethyl acetate mixture. The expected product is isolated after crystallization from isopropyl ether; M.p. = 151°C. (0.2H2O). Compounds III.2 to III.8 below are prepared in the same way: 80 Compound Ro M.p.; °C; (solvate) III. 2 142 III. 3 175 0,7 H20 III. 4 156 III.5 136 III.6 165 III.7 128 81 TABLE 7 (continuation 1) Compound Ro M.p.; °C; (solvate) III.8 151 EXAMPLE 37 5-Chloro-3-(2-chloro-4~fluorophenyl)-1-(2,4- dimethoxybenzyl)-3-methylindolin-2-one. CI. R3 = 4-OCH3; R4 = 2-OCH3; X = 5-C1; Y = H 0.34 g of potassium tert-butoxide is added at -40°C to a solution of 1.14 g of compound III.4 in 20 ml of tetrahydrofuran. The reaction mixture is stirred at 0°C for 5 minutes and then 0.32 ml of methyl iodide is added at -40°C. The reaction mixture is stirred for 2 hours at room temperature, then 10 ml of • a saturated aqueous ammonium chloride solution are added and extraction is carried out with ethyl acetate. The organic phase is dried over anhydrous sodium 'r- sulphate and then the solvents are evaporated under reduced pressure. The residue obtained, is crystallized from diisopropyl ether; M.p. = 1666C. The compounds of Examples 38. to 44 below are prepared in the same way, optionally purified by silica chromatography: r^ EXAMPLE Ro M.p.; °C; | salt, (solvate) 38 139 0.2 H20 39 161 0.4 H20 40 81 ~_ ■ ■ - — 41 155 42 I i i 140

Documents

Application Documents

#	Name	Date
1	in-pct-2002-01343-mum-form-pct-ipea-409-29-11-2002.pdf	2002-11-29
2	in-pct-2002-01343-mum-form 18(31-03-2005).pdf	2005-03-31
3	in-pct-2002-01343-mum-form 4-19-12-2005.pdf	2005-12-19
4	in-pct-2002-01343-mum-specification(amanded)-(27-12-2005).pdf	2005-12-27
5	in-pct-2002-01343-mum-power of authority-27-12-2005.pdf	2005-12-27
6	in-pct-2002-01343-mum-petition under rule 137-27-12-2005.pdf	2005-12-27
7	in-pct-2002-01343-mum-form 3(27-12-2005).pdf	2005-12-27
8	in-pct-2002-01343-mum-form 2(granted)-27-12-2005.pdf	2005-12-27
9	in-pct-2002-01343-mum-form 1a-27-12-2005.pdf	2005-12-27
10	in-pct-2002-01343-mum-claims(granted)-27-12-2005.pdf	2005-12-27
11	in-pct-2002-01343-mum-cancelled pages-27-12-2005.pdf	2005-12-27
12	in-pct-2002-01343-mum-wo international publication report(30-5-2006).pdf	2018-08-08
13	in-pct-2002-01343-mum-power of authority-30-9-2002.pdf	2018-08-08
14	in-pct-2002-01343-mum-other-30-9-2002.pdf	2018-08-08
15	in-pct-2002-01343-mum-form 5-30-9-2002.pdf	2018-08-08
16	in-pct-2002-01343-mum-form 3-30-9-2002.pdf	2018-08-08
17	in-pct-2002-01343-mum-form 2(title page)-(granted)-(14-2-2007).pdf	2018-08-08
18	in-pct-2002-01343-mum-form 2(title page)-(complete)-(30-9-2002).pdf	2018-08-08
19	in-pct-2002-01343-mum-form 2(granted)-(14-2-2007).pdf	2018-08-08
20	in-pct-2002-01343-mum-form 2(complete)-(30-9-2002).pdf	2018-08-08
21	in-pct-2002-01343-mum-description(granted)-(14-2-2007).pdf	2018-08-08
22	in-pct-2002-01343-mum-description(complete)-(30-9-2002).pdf	2018-08-08
23	in-pct-2002-01343-mum-correspondence.pdf	2018-08-08
24	IN-PCT-2002-01343-MUM-CORRESPONDENCE(RENEWAL PAYMENT LETTER) - (5-4-2007).pdf	2018-08-08
25	in-pct-2002-01343-mum-correspondence(ipo)-(22-2-2007).pdf	2018-08-08
26	in-pct-2002-01343-mum-correspondence(30-5-2006).pdf	2018-08-08
27	in-pct-2002-01343-mum-claims(granted)-(14-2-2007).pdf	2018-08-08
28	in-pct-2002-01343-mum-claims(amanded)-(30-5-2006).pdf	2018-08-08
29	in-pct-2002-01343-mum-claims(30-9-2002).pdf	2018-08-08
30	in-pct-2002-01343-mum-abstract(granted)-(14-2-2007).pdf	2018-08-08